PT  - JOURNAL ARTICLE
AU  - Sand, Andrea
AU  - Duffin, Aspen T.
AU  - Riddell, Geoffrey T.
AU  - Piacsek, Mitchel
AU  - Last, Brittany
AU  - Sun, Chaoyang
AU  - Rovin, Richard A.
AU  - Tjoe, Judy A.
AU  - Yin, Jun
TI  - Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast Cancer
AID  - 10.1101/2020.01.17.20017947
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.01.17.20017947
4099  - http://medrxiv.org/content/early/2020/01/24/2020.01.17.20017947.short
4100  - http://medrxiv.org/content/early/2020/01/24/2020.01.17.20017947.full
AB  - Despite the great improvement of patient outcomes by trastuzumab, a monoclonal antibody targeted on HER2-positive breast cancer, approximately 23% of patients with early-stage disease treated with adjuvant trastuzumab either fail to respond or experience recurrence within 10 years, highlighting the importance of identifying which HER2-positive patients would benefit from trastuzumab upfront. Efforts to identify biomarkers predictive of response to trastuzumab in initial breast tumor core biopsies have been complicated by the clinical and biological heterogeneity of HER2-positive tumors. Therefore, we identified a trastuzumab-resistant (TrR) signature that accurately predicts response to trastuzumab quantitively and qualitatively in vitro and in vivo, via repurposing transcriptome profiles in an engineered cell line model. We additionally demonstrated that our TrR signature was associated with tumor progression and capable of stratifying patient prognosis. Our study further illustrated the possible mechanism of this resistance as being less inherited cytotoxic T cell infiltration and failure to secrete Interferon-γ upon trastuzumab treatment in TrR tumors. These findings highlight the potential clinical application of TrR signature in treatment management and identifying possible immunotherapy interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is supported by Vince Lombardi Cancer Foundation and Aurora Health Care Seed Grant, Wisconsin, USA.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.